Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. (Q38019467)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Germaine Wong

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Jonathan Craig

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Jacob George

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

1 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

2172-2179

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22707355%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

5 February 2020

cites work

1 reference

Nonalcoholic fatty liver disease

21 January 2018

1 reference

Annual medical spending attributable to obesity: payer-and service-specific estimates

21 January 2018

1 reference

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

21 January 2018

1 reference

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.

21 January 2018

1 reference

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

21 January 2018

1 reference

Endpoints and clinical trial design for nonalcoholic steatohepatitis

21 January 2018

1 reference

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

21 January 2018

1 reference

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

21 January 2018

1 reference

Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application

21 January 2018

1 reference

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.

21 January 2018

1 reference

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

21 January 2018

1 reference

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

21 January 2018

1 reference

Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.

21 January 2018

1 reference

Minimal but significant improvement in survival for non-hepatitis C-related adult liver transplant patients beyond the one-year posttransplant mark

21 January 2018

1 reference

Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?

21 January 2018

1 reference

The direct cost of managing patients with chronic hepatitis B infection in Australia.

21 January 2018

1 reference

The cost of palliative care for hepatocellular carcinoma in Hong Kong.

21 January 2018

1 reference

Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening

21 January 2018

1 reference

Assessment of utilities and health-related quality of life in patients with chronic liver disease.

21 January 2018

1 reference

Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study.

21 January 2018

1 reference

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

Health-state utilities in liver disease: a systematic review.

21 January 2018

1 reference

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

21 January 2018

1 reference

Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis

21 January 2018

1 reference

Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors

21 January 2018

1 reference

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

Effects of thiazolidinediones on bone loss and fracture

21 January 2018

1 reference

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting

21 January 2018

1 reference

Health-State Utilities and Quality of Life in Hepatitis C Patients

21 January 2018

1 reference

Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis

21 January 2018

1 reference

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

21 January 2018

1 reference

7 January 2021

A position statement on NAFLD/NASH based on the EASL 2009 special conference

1 reference

7 January 2021

Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting

1 reference

7 January 2021

Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary

1 reference

7 January 2021

Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996)

1 reference

7 January 2021